Thromboembolic disease (TED) is a well-known preventable cause of morbidity and mortality in trauma patients. To improve their prognosis, pharmacological thromboprophylaxis, such as with low molecular weight heparins (LMWH), is an essential part of treatment. However, previously published studies have pointed out that standard dosing of LMWH may be associated with insufficient levels of activity measured using the anti-Xa parameter.

Polatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a component of the B-lymphocyte receptor typically expressed by diffuse large B-cell lymphoma (DLBCL) cells. In combination with bendamustine and rituximab (pola-BR), this drug is administered in the 3rd and subsequent lines of treatment for relapsed or refractory (R/R) DLBCL. If allogeneic hematopoietic stem cell transplantation (HSCT) is not feasible, patients with R/R DLBCL generally have a very poor prognosis, with limited further treatment options. However, at the 61st American Society of Hematology (ASH) congress held in December 2019 in Orlando, promising results were presented from extended follow-up of patients treated in clinical studies with the pola-BR combination.

Exacerbations of chronic obstructive pulmonary disease (COPD) significantly affect disease progression, quality of life, survival, and cardiovascular events. What to do about them and how to address them most effectively? Why should future treatment also focus more on mucus plugs? And why is it important to consider COPD even in healthy smokers? These topics were discussed by Professor Jadwiga Wedzicha from the National Heart and Lung Institute at Imperial College London during a symposium supported by Angelini at this year's XXVIII Hradec Pulmonary Days.

The work of a team of German and Dutch authors presents data on the real clinical use of 10% subcutaneous immunoglobulin facilitated by hyaluronidase (fSCIG) in elderly patients with primary (PID) or secondary (SID) immunodeficiency.

Patients with humoral immunodeficiency are indicated for immunoglobulin substitution therapy. The study presented below summarizes real-world data concerning the latest substitution method (i.e., facilitated subcutaneous administration) in paediatric patients.

According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), pulmonary rehabilitation is one of the most effective therapeutic interventions for reducing dyspnea, improving physical performance, and enhancing quality of life. Below, we summarize current insights on the effectiveness and possibilities of rehabilitation for these patients.

A mutation in the gene for alpha-1 antitrypsin (AAT), leading to its deficiency (AATD), causes progressive irreversible destruction of lung tissue. Patients develop chronic obstructive pulmonary disease (COPD) and early emphysema. Several studies evaluating COPD treatment have excluded patients with AATD. The aim of the following systematic literature review was to find and analyze works that include patients with concurrent COPD and AATD and summarize key findings that may form the basis for treatment decisions.

The authors of a study presented at the December congress of the American Society of Hematology (ASH) in Orlando introduced a new prognostic tool, m7-FLIPI, for determining the risk level of patients with follicular lymphoma (FL). They tested its utility using samples from the GALLIUM clinical trial and, during the analysis, discovered a promising biomarker that could help in selecting the primary chemotherapy for FL patients.

The prevalence of primary immunodeficiencies (PID) is estimated at 1 : 10,000. Below, we summarize the available findings on the efficacy and safety of subcutaneous immunoglobulin substitution in Ig-naive patients (i.e., without prior immunoglobulin substitution).

The treatment of patients with humoral immunodeficiency is long-term and therefore needs to be not only effective but also safe and well-tolerated. Below, we present the outcomes from an Italian real-world clinical practice study evaluating the efficacy, safety, and tolerability of human immunoglobulin for facilitated subcutaneous administration and patient satisfaction with this therapy.

For many patients with primary immunodeficiency, lifelong immunoglobulin substitution is essential to reduce the frequency of severe infections. Subcutaneous home administration is better accepted by patients. However, dosing needs to be customized to the patient. The study presented below may help make therapy individualization easier for doctors and more tolerable for patients.

A study by Czech authors published in 2020 demonstrated the usefulness of the MSKCC (Memorial Sloan Kettering Cancer Center) model in the prognostic stratification of patients with metastatic renal carcinoma (mRCC) treated with sunitinib in the 1st line. Additionally, a significant difference was found between the outcomes achieved in patients with intermediate risk who had one or two risk factors.

Meta-analyses regarding the use of thrombopoietin receptor agonists (TPO-RA) evaluated their efficacy and safety in the treatment of primary immune thrombocytopenia over long-term follow-ups. What findings did they uncover?

The authors from several American institutions examined the efficacy and safety of two proprotein convertase subtilisin/kexin type 9 (PCSK9i) inhibitors, alirocumab and evolocumab, in their work. They conducted a systematic meta-analysis of randomized controlled clinical trials comparing the administration of these two PCSK9i with standard treatment.

The use of glaucoma medications without preservatives has been a trend in recent years. You can try their clinical application in the role of a prescribing doctor in an interactive case study. Practical information about this popular local treatment is based on the evidence-based medicine foundation, provided by its author MUDr. Petr Výborný, CSc., from the Eye Clinic of the 1st Faculty of Medicine, Charles University and University Military Hospital in Prague.